Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 19/20 | 0.61 |
| ▸ | AGTR2 | P50052 | 13/20 | 0.60 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3748641 | 0.84 | AGTR1 (0.62) | AGTR1AGTR2LTB4R2ABCB11GP6 | |
| SCHEMBL489103 | 0.74 | AGTR1 (0.59) | AGTR1AGTR2LTB4R2ABCB11GP6 | |
| SCHEMBL489226 | 0.74 | AGTR1 (0.55) | AGTR1AGTR2LTB4R2ABCB11GP6 | |
| SCHEMBL1282321 | 0.74 | AGTR1 (0.53) | AGTR1AGTR2LTB4R2ABCB11GP6 | |
| SCHEMBL30602652 | 0.72 | AGTR1 (0.83) | AGTR1AGTR2LTB4R2ABCB11GP6 | |
| SCHEMBL3753609 | 0.71 | AGTR1 (0.42) | AGTR1AGTR2LTB4R2ABCB11GP6 | |
| SCHEMBL24490967 | 0.71 | AGTR1 (0.85) | AGTR1AGTR2LTB4R2ABCB11GP6 | |
| Abitesartan SCHEMBL489169 | 0.71 | AGTR1 (0.72) | AGTR1AGTR2LTB4R2ABCB11GP6 | |
| SCHEMBL18387996 | 0.70 | AGTR1 (1.00) | AGTR1AGTR2LTB4R2ABCB11GP6 | |
| SCHEMBL25014998 | 0.70 | AGTR1 (0.81) | AGTR1AGTR2LTB4R2ABCB11GP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236839-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-7834041-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| EP-2200975-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | Theravance, Inc. (US) | 2010-06-30 | — | — | EP | disclosed |
| US-20090093417-A1 | Dual-acting antihypertensive agents | THERAVANCE, INC. | 2009-04-09 | — | — | US | disclosed |
| WO-2009035543-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093417-A1 | Dual-acting antihypertensive agents | AGTR1, REN, AGTR2 | AGTR1 1/4885AGTR2 3/4885LTB4R2 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.